Ann: Quarterly Report and Appendix 4C, page-116

Reported today in New Atlas (from Lancet Public Health, by the Australian National Drug and Alcohol Research Centre, UNSW, Sydney).

It highlights the problems for medical cannabis research (and use) in Australia compared to Canada, the USA and Germany.

Yet another example of why EXL should concentrate on it's Hemp USA operations, and use company funds for USA expansion, and not get too caught up in costly long-term medical cannabis research in Australia. There is not going to be any money in it for decades.

(A purportedly flawed) controversial Australian study finds no evidence that cannabis helps chronic pain.
https://newatlas.com/australian-cannabis-chronic-pain-study/55298/

Everyone knows it does, from thousands of studies overseas.

I would like to know who funded the Australian study, my bet is big pharma.

Anyway, the conclusion reached by the medical journalist was as follows;

" In Australia, medical cannabis usage was only approved for a very limited number of conditions in 2016. While the United States and Canada are moving to more broadly allow recreational usages of the drug, Australia is moving much more slowly and conservatively. Despite the disappointing limitations of this study, and its conclusions being inconsistent with broader international research, it may slow down further medical cannabis legislation in the country (of Australia) over the coming years. "

Gw